Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Celldex Therapeutics Inc's Business Segments
Celldex Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Contracts and grants
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Contracts and grants0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Contracts and grants | - | 0% |
Revenue by Product & Service Category - FY
- Grant100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Grant | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- Contracts and grants0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Contracts and grants | - | 0% |
Description of Celldex Therapeutics Inc
Celldex Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapies for the treatment of various forms of cancer and other diseases. The company was founded in 1983 and is headquartered in Hampton, New Jersey, USA.
Celldex's approach to cancer treatment revolves around targeting the body's immune system to fight cancer cells. Their immunotherapy platform utilizes a unique combination of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and immune system modulators to target specific proteins or cells involved in the growth and progression of cancer.
The company's lead product candidate, CDX-301, is a human recombinant Flt3 ligand (Flt3L) designed to stimulate the production of immune cells, specifically dendritic cells and monocytes. Dendritic cells are crucial for initiating immune responses against cancer cells, and CDX-301 aims to enhance the body's immune response by increasing the number of these cells.
Another key product in Celldex's pipeline is CDX-1140, an agonist antibody that targets CD40, a protein found on the surface of immune cells called antigen-presenting cells. CD40 activation stimulates the immune system, leading to the activation and proliferation of various immune cells, including T-cells. CDX-1140 aims to harness the immune system's power to recognize and attack cancer cells.
Apart from these lead candidates, Celldex has a rich pipeline of other promising immunotherapies in various stages of development. CDX-3379 is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which is commonly overexpressed in several types of cancer, including head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CDX-0159 is a humanized monoclonal antibody targeting the mast cells, which are involved in various allergic and inflammatory diseases.
Celldex also has an innovative antibody-drug conjugate (ADC) platform called SMART (Stable, Modular Antibody Conjugation Technology). ADCs are designed to selectively deliver cytotoxic drugs to cancer cells, minimizing the damage to healthy cells. The SMART platform enables the efficient conjugation of small molecule drugs to antibodies, enhancing the therapeutic potential of ADCs.
In addition to its robust pipeline, Celldex has collaborations and partnerships with several pharmaceutical and biotechnology companies to leverage their expertise and resources. The company has also received grants and funding from various organizations, including the National Institutes of Health (NIH), to support its research and development efforts.
Overall, Celldex Therapeutics Inc. is a pioneering biopharmaceutical company committed to revolutionizing cancer treatment through innovative immunotherapies. With a diverse and promising pipeline, strategic collaborations, and a focus on leveraging the power of the immune system, Celldex aims to make a significant impact in the field of oncology and improve patient outcomes.
Celldex's approach to cancer treatment revolves around targeting the body's immune system to fight cancer cells. Their immunotherapy platform utilizes a unique combination of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and immune system modulators to target specific proteins or cells involved in the growth and progression of cancer.
The company's lead product candidate, CDX-301, is a human recombinant Flt3 ligand (Flt3L) designed to stimulate the production of immune cells, specifically dendritic cells and monocytes. Dendritic cells are crucial for initiating immune responses against cancer cells, and CDX-301 aims to enhance the body's immune response by increasing the number of these cells.
Another key product in Celldex's pipeline is CDX-1140, an agonist antibody that targets CD40, a protein found on the surface of immune cells called antigen-presenting cells. CD40 activation stimulates the immune system, leading to the activation and proliferation of various immune cells, including T-cells. CDX-1140 aims to harness the immune system's power to recognize and attack cancer cells.
Apart from these lead candidates, Celldex has a rich pipeline of other promising immunotherapies in various stages of development. CDX-3379 is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), which is commonly overexpressed in several types of cancer, including head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC). CDX-0159 is a humanized monoclonal antibody targeting the mast cells, which are involved in various allergic and inflammatory diseases.
Celldex also has an innovative antibody-drug conjugate (ADC) platform called SMART (Stable, Modular Antibody Conjugation Technology). ADCs are designed to selectively deliver cytotoxic drugs to cancer cells, minimizing the damage to healthy cells. The SMART platform enables the efficient conjugation of small molecule drugs to antibodies, enhancing the therapeutic potential of ADCs.
In addition to its robust pipeline, Celldex has collaborations and partnerships with several pharmaceutical and biotechnology companies to leverage their expertise and resources. The company has also received grants and funding from various organizations, including the National Institutes of Health (NIH), to support its research and development efforts.
Overall, Celldex Therapeutics Inc. is a pioneering biopharmaceutical company committed to revolutionizing cancer treatment through innovative immunotherapies. With a diverse and promising pipeline, strategic collaborations, and a focus on leveraging the power of the immune system, Celldex aims to make a significant impact in the field of oncology and improve patient outcomes.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development of innovative therapies for patients with cancer and other serious diseases. The company is known for its commitment to developing targeted protein therapies and novel approaches to treatment. Below is an extensive overview of the key segments, products, and services that Celldex Therapeutics offers:
1. Oncology Pipeline
Celldex Therapeutics primarily focuses on the oncology segment, developing antibody-drug conjugates (ADCs) and immune-oncology therapies. Their pipeline includes several promising candidates designed to target various types of cancers:
- CDX-014: This is an investigational antibody-drug conjugate designed to target the cell-surface protein, tissue factor, which is overexpressed in several tumors. It aims to deliver a potent cytotoxic agent directly to cancer cells, minimizing damage to normal tissues.
- CDX-301: A novel fusion protein designed to enhance the activity of dendritic cells and T-cells in the immune system. It is currently being studied for its use in combination with other cancer therapies.
- CDX-1307: Targeted at the glycoprotein 100 (gp100) antigen, CDX-1307 is in development to treat melanoma. It aims to stimulate T-cell responses against the tumor, enhancing the bodys immune response.
Immunotherapy
Celldex is involved in developing various immunotherapy products, which harness the body’s immune system to fight diseases, particularly cancer:
- Vaccine Platforms: The company has been developing vaccine candidates that can evoke strong immune responses against tumor-associated antigens.
- Monoclonal Antibodies: Celldex also works on monoclonal antibodies aimed at specific targets on cancer cells to inhibit tumor growth or to activate immune responses.
Research & Development Services
Celldex Therapeutics offers extensive capabilities in R&D services to support the development of innovative therapeutics:
- Preclinical and Clinical Development: The company conducts preclinical studies and clinical trials, demonstrating the effectiveness and safety of its drug candidates.
- Partnerships for Drug Development: Celldex collaborates with other biopharmaceutical companies and research institutions to advance the development of their therapeutic candidates.
Regulatory and Compliance
Celldex is involved in navigating the complex regulatory landscape applicable to biopharmaceutical products. This includes preparing submissions for investigational new drugs (IND) and new drug applications (NDA) with agencies such as the FDA.
Patient Support Programs
Recognizing the complexities involved in cancer treatment, Celldex may offer programs designed to support patients undergoing treatment with their therapies:
- Education and Resources: Providing educational materials and resources about novel therapies and clinical trial participation.
- Access Programs: Facilitating patient access to investigational drugs and providing support throughout the treatment process.
Collaborative Research Initiatives
The company also engages in collaborative research initiatives aimed at advancing the understanding of cancer biology and treatment through partnerships with academic institutions and other healthcare organizations.
Market Access and Health Economics
Celldex is engaged in activities related to market access to ensure that its products are available to patients in need. This may include:
- Health Economics and Outcomes Research: Gathering data on the value of their products and assessing the economic impact of their therapies in typical clinical settings.
- Pricing and Reimbursement Strategies: Working to define pricing strategies for optimal market access and facilitating conversations with payers.
Conclusion
Celldex Therapeutics, Inc. is dedicated to harnessing innovative biotechnology to develop specialized therapies that address the unmet needs in cancer treatment and other significant medical challenges. Their product pipeline, rich in immunotherapeutic and targeted therapy options, reflects their commitment to advancing patient care and improving outcomes through extensive research and collaboration.
1. Oncology Pipeline
Celldex Therapeutics primarily focuses on the oncology segment, developing antibody-drug conjugates (ADCs) and immune-oncology therapies. Their pipeline includes several promising candidates designed to target various types of cancers:
- CDX-014: This is an investigational antibody-drug conjugate designed to target the cell-surface protein, tissue factor, which is overexpressed in several tumors. It aims to deliver a potent cytotoxic agent directly to cancer cells, minimizing damage to normal tissues.
- CDX-301: A novel fusion protein designed to enhance the activity of dendritic cells and T-cells in the immune system. It is currently being studied for its use in combination with other cancer therapies.
- CDX-1307: Targeted at the glycoprotein 100 (gp100) antigen, CDX-1307 is in development to treat melanoma. It aims to stimulate T-cell responses against the tumor, enhancing the bodys immune response.
Immunotherapy
Celldex is involved in developing various immunotherapy products, which harness the body’s immune system to fight diseases, particularly cancer:
- Vaccine Platforms: The company has been developing vaccine candidates that can evoke strong immune responses against tumor-associated antigens.
- Monoclonal Antibodies: Celldex also works on monoclonal antibodies aimed at specific targets on cancer cells to inhibit tumor growth or to activate immune responses.
Research & Development Services
Celldex Therapeutics offers extensive capabilities in R&D services to support the development of innovative therapeutics:
- Preclinical and Clinical Development: The company conducts preclinical studies and clinical trials, demonstrating the effectiveness and safety of its drug candidates.
- Partnerships for Drug Development: Celldex collaborates with other biopharmaceutical companies and research institutions to advance the development of their therapeutic candidates.
Regulatory and Compliance
Celldex is involved in navigating the complex regulatory landscape applicable to biopharmaceutical products. This includes preparing submissions for investigational new drugs (IND) and new drug applications (NDA) with agencies such as the FDA.
Patient Support Programs
Recognizing the complexities involved in cancer treatment, Celldex may offer programs designed to support patients undergoing treatment with their therapies:
- Education and Resources: Providing educational materials and resources about novel therapies and clinical trial participation.
- Access Programs: Facilitating patient access to investigational drugs and providing support throughout the treatment process.
Collaborative Research Initiatives
The company also engages in collaborative research initiatives aimed at advancing the understanding of cancer biology and treatment through partnerships with academic institutions and other healthcare organizations.
Market Access and Health Economics
Celldex is engaged in activities related to market access to ensure that its products are available to patients in need. This may include:
- Health Economics and Outcomes Research: Gathering data on the value of their products and assessing the economic impact of their therapies in typical clinical settings.
- Pricing and Reimbursement Strategies: Working to define pricing strategies for optimal market access and facilitating conversations with payers.
Conclusion
Celldex Therapeutics, Inc. is dedicated to harnessing innovative biotechnology to develop specialized therapies that address the unmet needs in cancer treatment and other significant medical challenges. Their product pipeline, rich in immunotherapeutic and targeted therapy options, reflects their commitment to advancing patient care and improving outcomes through extensive research and collaboration.